The MATCH platform was developed by designing and synthesizing complementary Fab’‐MORF conjugates that self‐assemble into modular T cell engagers, enabling targeted recognition of BCMA, SLAMF7, and CD38 on MM cells. Here, TNFRSF17 is linked to Miyoshi myopathy.